Connecticut is currently home to 1213 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pilot RCT: FQHC Intervention for Uptake of CGM in Hispanic Adults with T1D
NCT06487962
Recruiting
Hispanics adults with type 1 diabetes (T1D), despite their disproportionate burden of acute complications (hypoglycemia and diabetes ketoacidosis) and related emergency department visits, hospitalizations, and death, remain largely disenfranchised from continuous glucose monitoring (CGM), an efficacious technology to mitigate these inequities. To increase CGM uptake in low-income, Hispanic adults with T1D receiving diabetes management in federally qualified health centers (FQHCs), this pilot ran... Read More
Gender:
ALL
Ages:
25 years and above
Trial Updated:
06/27/2024
Locations: Community Health Center, Inc., Middletown, Connecticut
Conditions: Type 1 Diabetes
Register for Updates
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
NCT06027840
Recruiting
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Cigarette Smoking, E-Cigarette Use, Smoking Cessation
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: St. Mary's Hospital, Waterbury, Connecticut
Conditions: Breast Cancer
Register for Updates
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
NCT04210492
Recruiting
The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Non-small Cell Lung Cancer
Register for Updates
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
NCT03847467
Recruiting
Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a dose dependent manner. The investigators will test 1, 5, or 10 gm 2'-FL compared to 2 gm dextrose placebo as a daily dietary supplement in pediatric and young adult IBD participants in stable remission receiving inflixi... Read More
Gender:
ALL
Ages:
Between 11 years and 25 years
Trial Updated:
06/24/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Register for Updates
Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
NCT04219540
Recruiting
This study seeks to compare the effectiveness of two medications used to treat opioid use disorder, extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX), among adults currently incarcerated in U.S. jails and prisons at 5 distinct trial sites. This open-label, non-inferiority, head-to-head study design will offer providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of XR-B (and XR-NTX) as po... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Opioid-use Disorder
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/20/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Hydrocephalus
Register for Updates
Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia
NCT03592290
Recruiting
To monitor the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
Gender:
ALL
Ages:
Between 20 years and 45 years
Trial Updated:
06/20/2024
Locations: John B. Pierce Laboratory, New Haven, Connecticut
Conditions: Hypovolemia, Hemodynamic Instability
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, New Haven, Connecticut
Conditions: Neoplasms
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
VItamin C in Thermal injuRY: The VICToRY Trial
NCT04138394
Recruiting
This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Bridgeport Hospital, Bridgeport, Connecticut
Conditions: Shock, Thermal Burn
Register for Updates
An Evaluation of Hip Preservation Outcomes
NCT05746533
Recruiting
The purpose of this study is to assess outcomes of hip preservation surgeries including open and arthroscopic treatment of femoroacetabular impingement (FAI).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/12/2024
Locations: Yale New Haven Health, New Haven, Connecticut
Conditions: Hip Arthroscopy, Femoroacetabular Impingement
Register for Updates